GLP-1 Success A better GLP-1 journey starts here Mike -135 LBS *Eligible patients lost an average of 21% of their body weight (-48 lbs) in a 72-week clinical trial evaluating 15 mg tirzepatide, when paired with diet and exercise
Practical, compliant applications in human and veterinary wellness
Second, improvements in IR and glycaemic indices are most apparent in higher-burden phenotypes, particularly in women with impaired glucose tolerance/prediabetes or related metabolic comorbidities, where changes in HOMA-IR, fasting glucose and OGTT profiles are more pronounced and may plausibly reduce periconception metabolic risk
And if youre taking any medications, theres always a risk that any supplement could interact with it
Evidence and UK Guidance Polycystic ovary syndrome (PCOS) affects approximately 10% of women of reproductive age in the UK, causing hormonal imbalances, irregular periods, and significant metabolic complications including insulin resistance and increased diabetes risk
This data supports the product's launch in 2014 as the first approved GLP-1 weight loss drug
